Apellis Pharmaceuticals, Inc. Common Stock
Here’s whether Apellis Pharmaceuticals, Inc. Common Stock (APLS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+16.66% over 10 days); strong 1-year return of +125.2%; 3-month momentum positive (+105.1%). Concerns: RSI 100 — overbought, elevated pullback risk; declining volume on rally — weak conviction (0.71x 30d avg). Currently 0.1% off its 52-week high. Score: +4/7.
APLS is in a confirmed uptrend, trading above both its 50-day ($25.52) and 200-day ($23.90) moving averages. With an RSI of 99.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +125.2% compares to +35.1% for SPY (beat the market by 90.1%).